Aehr Test Systems enters the back half of April with an uncomfortable combination: a massive month-long price surge drawing heavy insider selling, short sellers quietly rebuilding positions, and options traders showing the most defensive tilt in weeks.
The insider activity is the standout story this week. Executives at virtually every level sold shares in the days immediately following the stock's April 7 earnings-driven spike. The Founder and Chairman, Rhea Posedel, offloaded more than 17,700 shares across two transactions on April 21–22, realising over $1.77 million. An independent director sold 50,000 shares on April 21 for $4.75 million. The CEO, COO, CTO, and EVP all followed on April 27. The 90-day net insider value across all transactions is over $20 million sold. At a stock up 153% over the past month, the selling is rational — but the breadth and timing, concentrated in the week after a powerful earnings rally, adds a cautionary layer to the setup.
The short-selling side of the ledger reinforces that caution. Short interest jumped 34% over the past week, reaching nearly 17% of the free float — a level that places AEHR firmly in the crowded-short category for a semiconductor equipment name. That build happened sharply: shares short were around 3.8 million at the start of the week of April 21, then vaulted past 5 million by April 24 after the earnings bounce provided cover for new entrants. Despite the elevated SI, borrow conditions remain unusually relaxed. The cost to borrow is running near 0.48% — down roughly 30% over the past month and well below the levels seen when the stock was trading much lower in March. Availability has actually loosened as the stock rallied, pointing to ample supply for new shorts entering the trade. This is not a squeeze-risk setup: shorts have cheap, plentiful access to borrows.
Options positioning has shifted more defensive this week. The put/call ratio is running at 0.60, noticeably above its 20-day average of 0.46 and at a z-score of 1.65 — close to its most protective level of the past year (52-week high of 0.66). That uptick in put demand lines up with the insider selling and the short rebuild: multiple parts of the market are hedging or fading the April spike simultaneously. The ORTEX short score of 61.2, while off its peak of around 65 from mid-April, remains elevated and in the top 6% of all names by short-score rank.
The Street picture is complicated by stale consensus data. The analyst mean price target on file is roughly $64, well below the current price of $82. The most recent analyst action of note was William Blair's upgrade to Outperform in early March — when AEHR was trading at a fraction of today's level. Since then, the stock's 153% one-month move has outrun any published target. The analyst return potential score implies roughly -28% downside from current levels, meaning the Street as a whole is on record as seeing the stock as materially overvalued at these prices. Whether that leads to a wave of formal target lifts or downgrade pressure after the run becomes a watchpoint as the next earnings event approaches in early July.
Peers closed broadly weaker on the day, but the moves were modest. COHU fell around 4.4% on Tuesday, MPWR dropped 5.3%, and ONTO lost 5.3% — all week-on-week declines well within single digits. AEHR's 12% weekly decline is more severe, reflecting post-earnings reversion pressure specific to the name rather than a broad sector washout.
The next scheduled earnings event is July 8. Between now and then, the key variables are whether insider selling persists at these prices, whether the short interest build continues toward the 52-week utilisation highs last seen in March, and whether any analyst formally updates coverage to reflect the stock's transformed valuation after the April rally.
See the live data behind this article on ORTEX.
Open AEHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
